Based on the Hims Hers Health Inc stock forecast from 12 analysts, the average analyst target price for Hims Hers Health Inc is USD 24.59 over the next 12 months. Hims Hers Health Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Hims Hers Health Inc is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, Hims Hers Health Inc’s stock price was USD 27.60. Hims Hers Health Inc’s stock price has changed by -11.68% over the past week, +8.96% over the past month and +221.30% over the last year.
No recent analyst target price found for Hims Hers Health Inc
No recent average analyst rating found for Hims Hers Health Inc
Company Overview Hims Hers Health Inc
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California. Read Less
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products...Read More
Frequently Asked Questions About Hims Hers Health Inc (HIMS) Stock
Based on ratings from 12 analysts Hims Hers Health Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 7 buy, 2 sell and 9 hold ratings.
Unfortunately we do not have enough data on HIMS's stock to indicate if its a good dividend stock.
Based on targets from 12 analysts, the average taret price for HIMS is USD 24.59 over the next 12 months. The maximum analyst target price is USD 42 while the minimum anlayst target price is USD 18.
HIMS stock's Price/Earning ratio is 77.80.
Our analysis grades HIMS stock's Price / Earning ratio at F. This means that HIMS stock's Price/Earning ratio is above 92% of the stocks in the Household & Personal Products sector in the NYE exchange.
Based on this HIMS may be a overvalued for its sector.
The last closing price of HIMS's stock was USD 27.60.
The most recent market capitalization for HIMS is USD 7.48B.
Based on targets from 12 analysts, the average taret price for HIMS is projected at USD 24.59 over the next 12 months.
This means that HIMS's stock price may go down by -10.92% over the next 12 months.
We can't find any ETFs which contains Hims Hers Health Inc's stock.
As per our most recent records Hims Hers Health Inc has 1,046 Employees.
Hims Hers Health Inc's registered address is 2269 Chestnut Street, San Francisco, CA, United States, 94123.
You can get more information about it from Hims Hers Health Inc's website at https://www.forhims.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Hims Hers Health Inc (HIMS) Stock
Based on ratings from 12 analysts Hims Hers Health Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 7 buy, 2 sell and 9 hold ratings.
Unfortunately we do not have enough data on HIMS's stock to indicate if its a good dividend stock.
Based on targets from 12 analysts, the average taret price for HIMS is USD 24.59 over the next 12 months. The maximum analyst target price is USD 42 while the minimum anlayst target price is USD 18.
HIMS stock's Price/Earning ratio is 77.80.
Our analysis grades HIMS stock's Price / Earning ratio at F. This means that HIMS stock's Price/Earning ratio is above 92% of the stocks in the Household & Personal Products sector in the NYE exchange.
Based on this HIMS may be a overvalued for its sector.
The last closing price of HIMS's stock was USD 27.60.
The most recent market capitalization for HIMS is USD 7.48B.
Based on targets from 12 analysts, the average taret price for HIMS is projected at USD 24.59 over the next 12 months.
This means that HIMS's stock price may go down by -10.92% over the next 12 months.
We can't find any ETFs which contains Hims Hers Health Inc's stock.
As per our most recent records Hims Hers Health Inc has 1,046 Employees.
Hims Hers Health Inc's registered address is 2269 Chestnut Street, San Francisco, CA, United States, 94123.
You can get more information about it from Hims Hers Health Inc's website at https://www.forhims.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for HIMS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
